CA1202619A - Intermediates for the preparation of n-methyl 11-aza- 10-deoxo-10-dihydroerythromycin a - Google Patents

Abstract

ABSTRACT OF THE DISCLOSURE
Antibacterial N-methyl 11-aza-10-deoxo-10-dihydroerythromycin A and pharmaceutically acceptable acid addition salts thereof are prepared from the novel intermediate compound of the present invention.

Description

6~

This application is divided from applicants copending G~n~ n application Serial No. 432,606 filed July 18, 1983 which is directed to a compound oE the formula 0';"~

or a pharmaceutically acceptable acid addition salt thereof wherein R2 is hydrogen, alkanoyl having from 2 to 3 carbon atoms or 3-carbethoxypropionyl;
R3 is hydrogen, alkanoyl having from 2 to 3 carbon atoms or 3-carbethoxypropionyl.
This invention relates to a novel intermediate for the preparation of ll-aza-10-deoxo-10-dihydroerythromycin A a useful anti-bacterial agent, and to processes for the preparation of the intermediate.
Erythromycin AiS a macrolide antibiotic produced by fermentation and described in United States Patent No.2,653,899. Numerous derivatives of erythromycin A have been prepared in efforts to modify its biological and/or pharmacodynamic properties. Erythromycin A esters with mono- and dicarboxylic acids are reported in Antibiotics Annual, 1953-1954, Proc. Symposium Antibiotics (Washington, D.C.) pages 500-513 and 514-521, respectively. United States Patent No. 3,417,077 describes the cyclic carbonate ester of erythromycin A, the reaction product of erythromycin A
and ethylene carbonate, as an active antibacterial agent.

6~9 United States Patent 4,328,334, issued May 4, 1982, describes ll-aza-10-deoxo-10-dihydroerythromycin A, certain N-acyl- and N- (4-substituted benzenesulfonyl) derivatives thereof ~aving antibacterial properties, and a process for their preparation.
The alkylation of primary and/or secondary amine groups of compounds which include a tertiary amine group is generally complicated.
However, it is common practice to protect tertiary amine groups in such compounds by converting them to N-oxides prior to alkylation (Greene, "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., N.Y., 1981, pg. 281).
The present invention is useful in the preparation of compounds of formula I above.
According to the present invention, there is now provided a process for making a compound having formula (II) o UO, ~ )2 (II) \

which comprises reacting a compound of the formula ~2~2~g ~ HO, ~(CH3)2 HO/,/ ~ (IV~
HO

~ ~ '~

with an oxidizing agent in a reaction-inert solvent.
The present invention, together with that of aforementioned C~rt~fl;~n Application Serial No. 432,606, will now be described in more detail.
Also valuable for the same purpose as formula I compounds are the pharmaceutically acceptable acid addition salts thereof. Included among said salts, but by no means limited to said salts, are those enumerated below:
hydrochloride, hydrobromide, sulfate, phosphate, formate, acetate, propionate, butyrate, citrate, glycolate, lactate, tartrate, malate, maleate, Eumarate, gluconate, stearate, r~nd~l~te~ pamoate, benzoate, succinate, lactate, p-toluenesulfonate and aspartate.
Other intermediates of formula III and IIIA

H (~)n~ H~ ~ )2 HO I III n = 1 ~OC
- are described in a further copending divisional application~ 4~-

2~

The compounds of formula I can be named as N-methyl-ll-aza-4 -O(L-cladinosyl)-6-0-(D-desosaminyl)-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyloxacyclopentadecane-2-ones.
However, for simplicity, they are referred to herein as N-methyl derivatives of ll-aza-10-deoxo-10-dihydroerythromycin A, the nomenclature used in U.S. Patent 4,328,334.
The compound of formula II (R2 = R3 = H) is named in like manner as N hydroxy-ll-aza-10-deoxo-10-dihydroerythromycin A
N'-oxide, the term "Nl-oxide" referring to oxide formation on the dimethylamino group of the desosaminyl moiety. The alkylated structure of formula III (R2 = R3 = H) is named as N-metyl-ll-aza-10-deoxo-10-dihydroerythromycin bis N-oxide. The stereo-chemistry at the ll-aza atom of formula III is not yet known.
However, said formula III is intended to embrace the diastereomers.
As an alternative to the nomenclature used above, the parent compound of formula IV below can be named as 9-deoxo-9a-aza-9a-homoerythromycin A. Using this system the compounds of formula I wherein each of R2 and R3 is hydrogen is named 9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A.
Compounds of formula I and pharmaceutically acceptable acid addition salts thereof are effective antibacterial agents against gram-positive micro-organisms, e.g. Staphylococcus aureus and Streptococcus pyogenes, and against gram-negative micro-organisms, e.g. Pasturella multocida and Neisseria sicca. Ad-ditionally, they exhibit significant activity against Haemophilus _ vitro. The N-methyl derivative (formula I, R2 =
R3 - H), is superior to erythromycin A and ll-aza-10-deoxo-10-_ D~ --~z~

dihydroerythromycin A in its in vitro activity against Haemophilus.

d - 4a -6~L9 The N-methyl derivatives (formula I) surprising-ly and unexpectedly exhibit oral activity against gram-positive and gram-negative microorganisms. The N-methyl derivative of formula I (R2 = R3 = Hj S exhibits significant oral activity ln vlvo whereas no practical oral _ vivo activity is exhibited by 11-aza-10-deoxo-10-dihydroerythromycin A.

The N-methyl derivative of ll-aza-l~-aeoxo-10-dihydroerythromycin A (formula I) is prepared fromll-aza-10-deoxo-10-dihydroerythromycin A (formula IV) by the following reaction sequence:

HO N(CH3)2 HO" ~ ",O ~ H2O2 ~, ~ " ' ¢~X

IV Alkylating Agent I ~ Reduction III/III-A
The oxidation of ll-aza-10-deoxo-10-dihydro-erythromycin A is conducted in a reaction-inert solvent, i.e., one which does not react with reactants or products to produce undesired substances, under the conditions of the reaction, using as oxidizing agent hydrogen peroxide or a per acid such as peracetic acid, perbenzoic acid, m-chloroperbenzoic acid, permaleic acid and perphthalic acid.

The choice of solvent depends, in part, upon the oxidizing agent used. When using a water soluble oxidizing agent such as hydrogen ~eroxide or peracetic acid, a water miscible solvent should be used. When using oxidizing agents of low water solubility, e.g.
perbenzoic or m-chloroperbenzoic acid, an aqueous reaction mixture is generallv avoided in order to maintain a single phase reaction mixture.
Suitable solvents for use with the latter oxidizing agents are methylene chloride, chloroform, ethers, e.g. dioxane, tetrahydrofuran.
The oxidation is carried out at ambient tempera-ture; i.e., from about 18-25C, for reaction periods of up to 24 hours. An excess of oxidizing agent is used to ensure maximum conversion of ll-aza~10-deoxo-10-dihydroerythromycin A, the limiting reactant. In general, from about 1.0 mole to about 35 moles of oxidant per mole of said limiting reactant is used.
In practice, for the sa~e of economy, from about 5 to about 15 moles of oxidant are used per mole of the limiting reactant. Hydrogen peroxide is favored as oxidizing agent because of its availability. The amine oxide of formula II is isolated by extraction following removal or destruction of the excess oxidizing agent.
The amine oxide of formula I~ thus produced is then alkylated by reaction with an appropriate alkylating agent such as methyl iodide or bromide in a reaction-inert solvent and in the presence of an acid acceptor. Representative of reaction-inert solvents useful in this step are methylene chloride, chlorofor~, tetrahydrofuran and toluene. Suitable :~Z~26~L9 acid acceptors are inorganic bases such as alkali metal hydroxides and carbonates, and organic amines such as hindered amine bases, e.g. 2,6-lutidine, said substances being used in at least stoichiometric amount based on the alkylating agent used.
The alkylating agents are generally used in amounts based upon the amine oxide reactant ranging from equimolar to up to 100~ excess.
The alkylation reaction, when methyl iodide is used as alkylating agent, is conveniently carried out at ambient temperature. Alkylation by means of methyl bromide is sluggish at ambient temperatures, requiring prolonged reaction periods of several days.
When methyl bromide is used elevated temperatures, e.g. up to about 120C, are favored in order to expedite reaction.
An alternative alkylation procedure comprises the use of dimethyl sulfate in a reaction7inert solvent in the presence of an inorganic base such as those enumerated above. The reaction conditions when using dimethyl sulfate parallel those mentioned above for the methyl halides.
The intermediate products formed by alkylation of the formula II compound are isolated, if desired, by standard procedures such as evaporation of the reaction mixture following water wash thereof to remove inorganic salts. The reduction products ~formula I) of said intermediates are also isolated by standard procedures such as extraction.

Z6~L9 It has been found that alkylation of tne crude product resulting from tlle oxidation of IV, gives rise to two products; the compound of formula I~I
identified herein as N-~ethyl~ aza-10-deoxo-10-dihydroerythromycin A bis-N-oxide ~II; and the ~ono oxide (III-A) wherein oxide formation is at the desosaminyl nitrogen. Said compound is referred to herein as N-methyl-ll-aza-10-deoxo-10-dihydroerythro-mycin A desosaminyl-~-oxide.
The ahove-described inter~ediates need not be purified prior to their use in subsequent steps of the above reaction sequence. They can be used in crude form, i.e., as is, following their separation from their respective reaction mixtures. From the standpoint of convenience and economy the inter-mediates are generally not purified prior to their use in the process of this invention.
The third and final step of the reaction sequence, the reduction step, is carried out either catalytical-ly or chemically on the crude product of the alkylationreaction, or on the individual pure alkylated mono-and bis-oxides (IIIA and III). Catalytic reduction is carried out at ambient temperature (e.g. 18-25C) at hydrogen pressures of from about 1 to about 70 atmospheres in a reaction-inert solvent. Higher temperatures and pressures can be used, if desired, but offer no advantages.
Suitable catalysts are the noble metal catalysts, preferably supported, and certain salts thereof such as the oxides. ~epresentative catalysts are Pd/C, Rh/C, PtO2 and Raney nickel. The ratio of catalyst to substrate is not critical, but is generally in the range of from 1:1 to 1:2.

~2~)26~

g Typical solvents for the reduction step are Cl 4 alcohols, especially ethanol, ethyl acetate and ethers, e.g. tetrahydrofuran, dioxan.
In addition to the above-mentioned heterogeneous catalytic reduction, homogeneous catalysis using, for example, tris(triphenylphosphine)chlororhodium (I), known as the Wilkinson catalyst, can be used.
Suitable solvents for said reaction are those enumerat-ed above in connection with the heterogeneous catalyst procedure and in which the homogeneous catalyst is soluble. The concentration of homogeneous catalyst is not critlcal but, for reasons of economy, is generally kept at levels o from about 0.01 mole percent to about lO mole percent by weight based on the substrate.
The hydrogen pressure is not critical but, for the sake of convenience, is generally within the range of from about 1 to about 70 atmospheres.
In the above discussions of heterogeneous and homogeneous catalysisr even though the amounts of catalyst which would be used are not generally considered "catalytic" in the normal usage of this term, they are considered as catalytlc here since little or no reaction would occur in their absence.
The temperature of the catalytic reductions, heterogeneous or homogeneous, is not critical, but càn vary from about 20C to about 100C. The favored temperature range is from 20 to 80C.
Chemical reduction of the alkylated amine oxides (III~A a~d III) is accomplished by means of metal hydrides such as sodium borohydride, sodium cyano-borohydride, pyridine-SO3/potassium iodide, or zinc/glacial acetic acid.

~L2~ 9 Compounds of formula I wherein ~2 and/or R3 are alkanoyl as herein defined are conveniently prepared by standard acylation procedures such as those described by Jones et al., J. Med. Chem. 15, 631 (1972), and by Banaszek et al., Rocy. Chem. 43, 763 (1969). The 2'- and 4"-hydroxy groups are acylated by means of the appropriate acid anhydride [e.g.
(R2CO)2O] in pyridine. Solvolysis of the 2',4"-ester with methallol produces the 4"-ester.
Formation of mixed esters, e.g. 2'-acetyl-4"-propionyl-, is readily achieved by aeylating the 4"-ester (R3 = propionyl) with acetie anhydride in a reaetion-inert solvent in the presence o~ pc,tassium earbonate aceording to the procedure for mi~ed esters deseribed by Jones et al. (loc. cit.).
Aeid addition salts of the compounds oE for~nula I
are r~adily prepared by treating compounds having formula I with at least an equimolar amount of the appropriate aeid in a reaetion-inert solvent or, in the ease of the hydrochloride salts, with pyri-dinium hydroehloride. Sinee more than one basie group is present in a eompound of formula I, the addition of suffieient aeid to satisfy eaeh basie group permits formation of polyaeid addition salts.
When preparing aeid addition salts of formula I
eompounds wherein R2 is alkanoyl, isopropanol is used as solvent to avoid solvolysis of the alkanoyl group.
The acid addition salts are reeovered by filtration if they are insoluble in the reaetion-inert solvent, by preeipitation by addition of a non-solvent for the aeid addi-tion salt, or by evaporation of the solvent.
A variety of gram-positive mieroorsanisms and eertain gram-negative microorganisms, such as those of spherieal or ellipsoidal shape (coeei), are susceptible to eompounds of formula I. Their in ~Z~Z6~

~11-vitro activity is readily demonstrated by in vitro tests against various microorganisms in a brain-heart infusion medium by the usual two-fold serial dilution teehnique. Their in vitro activity renders them useful for topical application in the form of ointments, ereams and the like, for sterilization ourposes, e.g.
siek-room utensils; and as industrial antimicrobials, for e~ample, in water tre2tment, slime eontrol, paint and wood preservation.
For _ vitro use, e.g. for topical application, it will often be convenient to co~pound the seleeted produet with a pharmaceutically-acceptable carrier sueh as vegetable or mineral oil or an emollient eream. Similarly, they may be dissolved or dis?ersed in liquid earriers or solvents, such as water, aleohol, ~lyeols or mixtures thereof or other pharma-eeutieally-aeceptable inert media; that is, media whieh have no harmful effect on the active ingredient.
For such purposes, it will generally be acceptable to employ eoncentrations of active ingre~ient of from about 0.01 percent up to about 10 percent by weight based on total eomposition.
Additionally, many of the compou~ds are aetive versus gram-positive and eertain gram-negative micraorganisms in vivo via the oral and/orparenteral routes of administration in animals, ineluding man. Their in vivo aetivity is more limited as regards susceptible organisms and is determined by the usual proeedure which eomprises infecting miee of substantially uniform weight with the test organism and subsequently treating them orally or subcutaneously with the test compound, In praetiee, the mice, e.g. 10, are given an intra-peritoneal inoculation of suitably diluted eultures eontaining approximately 1 to 10 times the LDloo ~2~6~

(the lowest concentration of organisms required to produce 100~ deaths). Control tests are simultaneous-ly run in which mice receive inoculum of lower dilu~ions as a check on possible variation in virulence o~ the test organism. The test compound is administered 0.5 hour post-inoculation, and is repeated 4, 24 and 48 hours later. Surviving mice are held for 4 days after the last treatment and the number of survivors is noted.
When used ln vivo, these novel compounds can be administered orally or parenterally, e.g. by sub-cutaneous or intramuscular injection, at a dosage of from about 1 mg/kg to about 200 mg/kg of body weight per day. The favored dosage range is from about 5 mg/kg to about 100 mg/kg of body weight per day and the preferred range from about 5 mg/kg to about 50 mg/kg of body weight per day. Vehicles suitable for parenteral injection may be either aqueous such as water, isotonic saline, isotonic dextrose, Ringer's solution or non-aqueous such as fatty oils of vegetable origin (cotton seed, peanut oil, corn, sesame), dimethylsuloxide and other non-aqueous vehicl'es wh'ich will not interfere with therapeutic efficiency of the preparation and are non-toxic in the volume or proportion ùsed tglycerol, propylene glycol, sorbitol).
Additionally, compositions suitable for extemporaneous preparation of solutions prior to administration may advantageously be made. Such compositions may include liquid diluents; for example, propylene glycol, diethyl carbonate, glycerol, sorbitol, etc.;
buffering a~ents, hyaluronidase, local anesthetics and inorganic salts to afford desirable pharmacological properties. These compounds may also be combined with various pharmaceutically-acceptable inert Z~9 carrlers including solid diluents, aqueous vehicles, non-toxic organic solvents in the form of capsules, tablets, lozenges, troclles, dry mixes, suspensions, solutions, elixirs and parenteral solutions or suspensions. In general, the compounds are used in various dosage forms at concentration levels ranging from about 0.5 percent to about 90 percent by weight of the total composition.
In the Examples presented herein, no effort was made to recover the maximum amount of product produced or to optimize the yield of a given product. The Examples are merely illustrative of the process and of the praducts obtainable thereby.

~L2C~Z6~9 N-Hydroxy~ aza-10-deo~o-10-dihydro-erythromycin A ~'-oxide (Formula II) To a solution of ll-aza-10-deoxo-10-dihydro-erythromycin ~ (10.0 g) in 40 ml of methanol, a totalof 50 ml of 30% aqueous hydrogen peroxide was added dropwise while stirring over a 5-10 minute period.
After stirring overnight at ambient temperature, the reaction mixture was poured onto a stirred slurry of ice (200 g), ethyl acetate (200 ml), and water (100 ml). Excess hydroyen peroxide was quenched by cautious dropwise addition of saturated aqueous sodlum sulfite until a negative starch-iodine test was indicated. The layers were separated; and the aqueous layer was washed twice with 200 ml portions of ethyl acetate. The three organic extracts were combined, dried over anhydrous sodium sulfate, and evaporated to afford crude ~-hydroxy-ll-aza-10-deoxo-10-dihydroerythromycin A N'-oxide as a colorless foam (8.6 g).
While the crude product proved satisfactory for use in the preparative procedure described below, purification was readily achieved ~y silica gel chromatography, eluting with a methylene chloride:
methanol:concentrated ammonium hydroxide system (12:1:0.1). Progress of the column was followed by thin layer chromatography on silica gel plates using the system methylene chloride:methanol:concentrated ammonium hydroxide (9:1:0.1). The plates were developed with a vanillin spray [ethanol (50 ml): 85 H3PO4 (`50 ml):vanillin (1.0 g)] indicator with heat.
Hnmr (CDC13) delta 3.21 [6H, s, (CH3)2~-~o], 3.39 (3H, s, cladinose cH3o~ S: major 2eaks at m/e 576 (ion from desosamine fragmentation), 418 (aglycone ion-minus both sugars). Both pea~s are diagnostic for ~ OH moiety within aglycone.

312()26~

In like manner, but substituting hydrogen peroxide by an equivalent amount of peracetic acid, the same compound is produced.

N-Methyl-ll-aza-10-deoxo-10-dihydro-erythromycin A bis-N-oxide (Formula III) To a stirred mixture of N-hydroxy-ll-aza-10-deoxo-10-dihydroerythromycin A Nl-oxide (4.83 g), methylene chloride (100 ml) and solid anhydrous potassium carbonate (69.7 g), was added 15.7 ml ~35.8 g) o~ iodomethane dropwise under nitrogen over two minutes. The mixture was stirred under nitrogen at ambient temperature for 3.5 hours and the solid which formed recovered by filtration. The filter cake was washed with methylene chloride (250 ml), the filtrate and wash solutions were combined, water (300 ml) was added, and the pH of the vigorously stirred mixture ad~usted to 11. The organic phase was separated, dried with anhydrous sodium sul~ate, and concentrated to afford crude product as a color-less foam (4.36 g).
While the crude product proved satisfactory for use in the reduction procedure described below, purification was readily achieved by the technique commonly known as "Flash" silica gel chromatography [W. Clark Still, et al., J. ~. Chem. 43, 2923 (1978)] utilizing 230-400 mesh silica g~ (silica gel/crude material about 45/1 by weight), eluting by the "flash technique" with acetone/methanol = 4/1 by volume. The 10 ml collected ~ractions shown to be pure bis-N-oxide by thin layer chromatography (TLC
eluting system:methylene chloride:methanol:concen-trated ammonium hydroxide = 6:1:0.1; vanillin:85 H3PO4:ethanol spray indicator used with heat on ~2(~26~9 silica gel plates) were combined. From 1 gram of crude product, 128 mg of pure bis-o~ide was obtained.
l~nmr (CDC13) delta 3.20 [9H, broad s, aglycone CH3-N--~O and (CH3)2 , j, 3.39 (3H, s, cladinose CH30-); MS: m/e 461, and 431, 415 (these two peaks are diagnostic for aglycone `N-oxide), 1~9 (cladinose-derived fragment), 115 (desosamine N-oxide derived fragment).
The above-described chromatographic procedure also afforded a second, less polar product from the crude: N-methyl-ll-a~a-10-deoxo-10-dihydxoerythro-mycin A desosaminyl-N-oxide (246 mg).
Hnmr (CDC13) delta 2.30 (3H, s, aglycone CH3-~-), 3.18 [6H, s, (CH3)2-N-~0], 3.37 (3H, s, cladinose CH30-); MS: major peaks at m/e 461, 156, 115.

N-Methyl~ll-aza-10-deoxo-10-dihydroerythromycin A
A solution of the crude prcduct of Example 2, comprising N-methyl-ll-aza-10-deoxo-10-dihydroerythro-mycin A desosaminyl-N-oxide and N-methyl-ll-aza-10-deoxo-10-dihydroerythromycin A bis-N-oxide (4.36 g), in 150 ml of absolute ethanol was hydrogenated on a Parr apparatus (3.52 kg/m ; ~.0 g 10~ palladium on carbon catalyst; ambient temperature) for 1 1/4 hours. The catalyst was filtered, and the resulting filtrate was evaporated to dryness, affording a colorless foam ~4.3 g). The crude produc-t was taken up in methylene chloride (100 ml) and then stirred with water (100 ml) while the pH of the mi~ture was adjusted to 8.8. The organic and aqueous layers were separated. The aqueous layer was then extracted twice with 50 ml portions of methylene chloride. The three organic extracts were combined, dried over anhydrous sodium sulfate and evaporated to afford a ~2026~9 -17~

colorless foam (3.0 g). The entire sample was dissolv~d in 11 ml of warm ethanol, and water was added until the solution became slightly turbid.
~pon standing overni~ht, 1.5 g of the title product crystallized from solution; m.p. 136C, dec. A
recrystallization by the same procedure raised the melting point to 142C, dec. lHnmr (CDC13) delta 2-31 [6H, s, (CH3)2N-], 2.34 (3H, s, aglycone CH3-N-);
Cnmr [CDC13, (CH3)4Si internal standard] ppm 178.3 (lactone, C = O), 102~9 and 94.8 (C-3, C-5), 41.6 (aglycone CH3-N-), 40.3 [(CH3)2-N-~; MS: m/e 590, 432, 158.

N-~lethyl-11-aza-10-deoxo-10-dihydroerythromvcin A
The pure N-methyl-ll-aza-10-deoxo-10-dihydro-erythromycin ~ bis-N-oxide of Example 2 (20 mg) was hydrogenated according to the procedure of Example 3.
Thin layer chromatography ~ith the system methylene chloride:methanol:concentrated ammonium hydroxide (9:1:0.1) and the use of a vanillin spray as indicator (see Example 2) with heat on silica gel plates sho~ed a single, uniform product. Its lHnmr and TLC Rf values were identical to those of the product of Example 3. Yield: 60~.

12026~l9 N-Methyl-ll-aza-lO-deoxo-10-dihydroervthromycin A
A solution of crude product of Example 2 compris-ing N-methyl-ll-aza-10-deoxo-10-dihydroerythromycin A
desosaminyl-N-oxide and ~-~ethyl-ll-aza-lO-deoxo-lO-dihydroerythromycin A bis-N-oxide (10.0 g) in lS0 ml of absolute ethanol was hydrogenated on a Parr apparatus [3.52 kg/m2; 15 g of Raney-Mic~el catalyst (water-wet sludge); ambient temperature] for 1 1/2 hours. Work~up as described in Example 3 af~orded 8.5 g of the title product, with TLC R~ values identical to those of ~xample 3~

N-Methyl-ll-aza-lO-deoxo-lO-dihydroerythromycin A
A solution of N-methyl-ll-aza-lO-deoxo-10-dihydroerythromycin A desosaminyl-N-oxide (15 mg) in ethanol (5 ml) was hydrogenated at 2 psi using 5 mg 5% Pd-C catalyst for 3 hours. Filtration of the catalyst and solvent rernoval ln vacuo produced the title compound (98~ yield) as a colorless foam. Its Hnmr and TLC Rf values were identicai to those of the product of Example 3.

N-Methyl-ll-aza-lO-deoxo-lO-dihydroerythromycin A Hydrochloride To a solution of N-methyl-ll-aza-lO-deoxo-lO-dihydroerythromycin A (0.2 g, 0.27 mmole) in 50 ml of ethanol (absolute) is added an equimolar amount of hydrogen chloride and the reaction mixture stirred at room temperature for one hour. Removal of the solvent by evaporation under reduced pressure affords the mono-hydrochloride salt.

12~z~L9 In like manner, the hydrobromide, acetate, sulfate, butyrate, citrate, glycolate, stearate, pamoate, p-toluenesulfonate, benzoate and as~artate salts of N-methyl~ aza-10-deoxo-10-dihydroerythro-mycin A, are prepared.
Repetition of this prGcedure but using twice the amount of acid affords the di-acid salts of said N-methyl derivative.

N-Methyl-ll-aza-10-deoxo-10-dihydroerythromcyin ~ bis-Hydrochloride To a solution of 2.00 g of N-methyl-ll-aza-10-deoxo-lO-dihydroerythromycin A in 50 ml of methylene chloride, a solution of 308 mg of pyridinium hydro-chloride in 25 ml o methylene chloride was added dropwise over several minutes. The mixture was concentrated to a brittle foam (2.35 g), was thorough-ly pulverized in the presence of 125 ml of water.
The clear aqueous solution was decanted from the water-insoluble residue and lyophilized to afford the bis-hydrochloride salt of N-methyl ll-aza-10-deoxo-lO-dihydroerythromycin A as a colorless amorphous foam (1.21 g).
Analysis: Calc~d. for C38H72l2N2.
8.65~ Cl Found: 8.89~ Cl.
Treatment of a small portion of the water-soluble product with agueous sodium bicarbonate afforded a water-insoluble product having identical TLC Rf characteristics to those described above for N-methyl~ll-aza-10-deoxo-lO-dihydroerythromycin A
free base.

~Z~Z61g 2',4"-Diacetyl-N-methyl-ll-aza-10~
deoxo-10-dihydroerythromycin A
A solution of N-methyl-ll-aza-10-deoxo 10-dihydroerythromycin ~ (1.5 g, 2 mmole) in pyridine (50 ml) and acetic anhydride (30 ml~ is allowed to stand at room temperature for 3 days. It is then poured over ice and the pH adjusted to 9 ~ith 20%
NaOH (w/w) solution. Extraction of the mixture with chloroform ~3 x 50 ml) followed by drying the combined extracts (over K2CO3J and evaporation of the solvent under reduced pressure affords the title compound.
Repetition of this procedure but using propionic anhydride or 3~carbethoxypropionic anhydride as acylating agents affords the appropriate 2l,4"-diacyl derivatives.

4"-Acetyl-N-methyl-ll-aza-10-deoxo-10-dihydroerythromcyin A
2',4"~Diacetyl-N-methyl-10-deoxo-10-dihydro-er~thromycin A (1.0 ~) is dissolved in 100 ml of methanol and allowed to stand 3 days at room temper-ature. Evaporation of the methanol under reduced pressure affords the title product.
Solvolysis of the 2',4"-dipropionyl- and the 2',4" 3-carbethoxypropionyl derivatives of Example affords the corresponding 4"-propionyl- and 4"-(3-carbethoxypropionyl)-derivatives.

Claims (3)

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. A process for making a compound having formula (II) (II) which comprises reacting a compound of the formula (IV) (IV) with an oxidizing agent in a reaction-inert solvent.

2. The process of claim 1 wherein the oxidizing agent is hydrogen peroxide.

3. A compound of formula (II) as defined in claim 1, whenever prepared by the process of claim 1, or by an obvious chemical equivalent thereof.